Skip to Main Content

Paper Details

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Clin Cancer Res
121
2020
Author NameAffiliation
Jochen K LennerzCenter for Integrated Diagnostics, Massachusetts General Hospital
Subba R DigumarthyMassachusetts General Hospital
Rebecca NagyInc.
Cyril H BenesMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital
Cyril H BenesHarvard Medical School
Michael S LawrenceMassachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital
  • 1 - 6

Datasets

Release 1.2